Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H25NO |
Molecular Weight | 271.3972 |
Optical Activity | ( + ) |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)C2=C1
InChI
InChIKey=MKXZASYAUGDDCJ-NJAFHUGGSA-N
InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1
Molecular Formula | C18H25NO |
Molecular Weight | 271.3972 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/27139517Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2694543
http://www.who.int/medicines/areas/quality_safety/5.1Dextromethorphan_pre-review.pdf
http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21620_mucinex_lbl.pdf
https://www.ncbi.nlm.nih.gov/pubmed/25420446
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27139517
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2694543
http://www.who.int/medicines/areas/quality_safety/5.1Dextromethorphan_pre-review.pdf
http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21620_mucinex_lbl.pdf
https://www.ncbi.nlm.nih.gov/pubmed/25420446
Dextromethorphan is a non-narcotic morphine derivative widely used as an antitussive for almost 40 years. It has attracted attention due to its anticonvulsant and neuroprotective properties. It is a cough suppressant in many over-the-counter cold and cough medicines. In 2010, the FDA approved the combination product dextromethorphan/quinidine for the treatment of pseudobulbar affect. Dextromethorphan suppresses the cough reflex by a direct action on the cough center in the medulla of the brain. Dextromethorphan shows high-affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist and acts as a non-competitive channel blocker. It is one of the widely used antitussives and is used to study the involvement of glutamate receptors in neurotoxicity. Dextromethorphan (DM) is a sigma-1 receptor agonist and an uncompetitive NMDA receptor antagonist. The mechanism by which dextromethorphan exerts therapeutic effects in patients with pseudobulbar affect is unknown. Dextromethorphan should not be taken with monoamine oxidase inhibitors due to the potential for serotonin syndrome. Dextromethorphan is extensively metabolized by CYP2D6 to dextrorphan, which is rapidly glucuronidated and unable to cross the blood-brain barrier.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24678061
Curator's Comment: # in a Swiss and US patent application from Hoffmann-La Roche in 1946 and 1947, respectively
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL287 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15723099 |
205.0 nM [Ki] | ||
Target ID: CHEMBL4787 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2897648 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | MUCINEX DM Approved UseHelps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive: temporarily relieves: cough due to minor throat and bronchial irritation as may occur with the common cold or inhaled irritants; the intensity of coughing; the impulse to cough to help you get to sleep Launch Date2004 |
|||
Primary | NUEDEXTA Approved UseNUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury. Launch Date2010 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
599 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXTRORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
7.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
709 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXTRORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
15.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
95.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
124.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE |
DEXTRORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
123.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE |
DEXTRORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
68 nM*h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01361217 |
30 mg single, oral dose: 30 mg route of administration: oral experiment type: single co-administered: |
DEXTROMETHORPHAN plasma | Homo sapiens population: healthy age: adults sex: food status: |
|
17.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
32 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2898 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXTRORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
52 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3608 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXTRORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
133.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1049 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
933.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE |
DEXTRORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1000.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE |
DEXTRORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
50 mg 4 times / day steady, oral Dose: 50 mg, 4 times / day Route: oral Route: steady Dose: 50 mg, 4 times / day Sources: |
unhealthy, 19-52 years Health Status: unhealthy Age Group: 19-52 years Sex: M+F Sources: |
|
960 mg 1 times / day multiple, oral Highest studied dose Dose: 960 mg, 1 times / day Route: oral Route: multiple Dose: 960 mg, 1 times / day Sources: |
unhealthy, 19-67 years Health Status: unhealthy Age Group: 19-67 years Sex: M+F Sources: |
|
120 mg single, oral Recommended |
healthy, 26.5 years Health Status: healthy Age Group: 26.5 years Sex: M+F Sources: |
|
900 mg single, oral Overdose |
unknown, 27 years |
Other AEs: Ischemic colitis... |
270 mg single, oral Overdose |
unknown, 3 years |
Other AEs: Lethargy, Ataxia... Other AEs: Lethargy (1 patient) Sources: Ataxia (1 patient) Nystagmus (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Ischemic colitis | 1 patient | 900 mg single, oral Overdose |
unknown, 27 years |
Ataxia | 1 patient | 270 mg single, oral Overdose |
unknown, 3 years |
Lethargy | 1 patient | 270 mg single, oral Overdose |
unknown, 3 years |
Nystagmus | 1 patient | 270 mg single, oral Overdose |
unknown, 3 years |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/11602530/ Page: 2.0 |
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021879Orig1s000OtherR.pdf#page=63 Page: 63.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Differential effects of morphinan drugs on haloperidol-induced catalepsy in rats: a comparative study with an N-methyl-D-aspartate antagonist. | 1991 Mar-Apr |
|
The need for rational therapeutics in the use of cough and cold medicine in infants. | 1992 Apr |
|
Visual hallucinations after combining fluoxetine and dextromethorphan. | 1992 Oct |
|
Acute abstinence syndrome following abrupt cessation of long-term use of tramadol (Ultram): a case study. | 2000 |
|
Mimicking gene defects to treat drug dependence. | 2000 |
|
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. | 2001 Aug |
|
Prediction models in the design of neural network based ECG classifiers: a neural network and genetic programming approach. | 2002 |
|
A sensitive LC-MS/MS assay for the determination of dextromethorphan and metabolites in human urine--application for drug interaction studies assessing potential CYP3A and CYP2D6 inhibition. | 2002 Aug 22 |
|
Consultation with the specialist: the central serotonin syndrome: paradigm for psychotherapeutic misadventure. | 2002 Dec |
|
Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. | 2002 Dec |
|
Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. | 2002 Dec |
|
Bridging sectors. Medicon Valley. | 2002 Dec 12 |
|
The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. | 2002 Jan |
|
Biotechnology in the Medicon Valley. | 2002 May |
|
Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. | 2002 May |
|
Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. | 2004 Apr |
|
Effect of dextromethorphan, diphenhydramine, and placebo on nocturnal cough and sleep quality for coughing children and their parents. | 2004 Jul |
|
Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children. | 2004 Jul |
|
Evaluation of the One-Step ELISA kit for the detection of buprenorphine in urine, blood, and hair specimens. | 2004 Jul 16 |
|
Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. | 2004 May |
|
Bladder emptying over a period of 10-45 years after a traumatic spinal cord injury. | 2004 Nov |
|
[Dextromethorphan enhances analgesic activity of propacetamol--experimental study]. | 2005 |
|
High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. | 2005 |
|
Characterization of microsomal cytochrome P450-dependent monooxygenases in the rat olfactory mucosa. | 2005 Aug |
|
Effect of dextrometorphan and dextrorphan on nicotine and neuronal nicotinic receptors: in vitro and in vivo selectivity. | 2005 Feb |
|
Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. | 2005 Jan |
|
MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity. | 2005 Jul 19 |
|
Cytochrome P450 2D6 (CYP2D6) inhibitory constituents of Catharanthus roseus. | 2005 Jun |
|
Dextromethorphan-induced neurologic illness in a patient with negative toxicology findings. | 2006 Jun 27 |
|
Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. | 2006 May |
|
Mesenteric artery clamping/unclamping-induced acute lung injury is attenuated by N-methyl-D-aspartate antagonist dextromethorphan. | 2006 Nov-Dec |
|
Bench-to-bedside review: mechanisms and management of hyperthermia due to toxicity. | 2007 |
|
Cough mixture abuse as a novel cause of folate deficiency: a prospective, community-based, controlled study. | 2007 Apr |
|
Treatment of the common cold. | 2007 Feb 15 |
|
In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies. | 2007 Jul |
|
Free energies of binding of R- and S-propranolol to wild-type and F483A mutant cytochrome P450 2D6 from molecular dynamics simulations. | 2007 Jul |
|
Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal. | 2007 Jun 1 |
|
Mechanical aspects of a multidirectional, angular stable osteosynthesis system and comparison with four conventional systems. | 2008 Apr |
|
Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain. | 2008 Apr |
|
Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias. | 2008 Jan 8 |
|
Anti-inflammatory effects of dimemorfan on inflammatory cells and LPS-induced endotoxin shock in mice. | 2008 Jul |
|
Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening. | 2008 Jul |
|
Life-threatening dextromethorphan intoxication associated with interaction with amitriptyline in a poor CYP2D6 metabolizer: a single case re-exposure study. | 2008 Jul |
|
Effects of repeated cycles of sterilisation on the mechanical characteristics of titanium miniplates for osteosynthesis. | 2008 Sep |
|
Effect of fenofibrate on microcirculation and wound healing in healthy and diabetic mice. | 2009 |
|
Dextromethorphan reduces oxidative stress and inhibits atherosclerosis and neointima formation in mice. | 2009 Apr 1 |
|
Amyotrophic lateral sclerosis. | 2009 Feb 3 |
|
Characterization of retrieved orthodontic miniscrew implants. | 2009 Jan |
|
Retrospective analysis of titanium plate-retained prostheses placed after total rhinectomy. | 2009 Jan-Feb |
|
[Bone anchored hearing aids (BAHA)]. | 2009 Mar |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/1503667
https://www.ncbi.nlm.nih.gov/pubmed/26000221
15-30 mg 3 to 4 times per day (cough)
20-30 mg twice daily (pseudobulbar affect)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24912029
In vitro studies pre- and immature oligodendroglial (OLN-93) cells were subjected to hyperoxic conditions for 48 h after pre-treatment with increasing doses of dextromethorphan.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:45:38 GMT 2025
by
admin
on
Mon Mar 31 17:45:38 GMT 2025
|
Record UNII |
7355X3ROTS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type |
---|
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000181821
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
||
|
CFR |
21 CFR 341.14
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
||
|
CFR |
21 CFR 341.74
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
||
|
WHO-VATC |
QN07XX59
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
||
|
WHO-VATC |
QR05DA09
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
||
|
WHO-ATC |
R05DA09
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
||
|
NDF-RT |
N0000182149
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
||
|
WHO-ATC |
N07XX59
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
||
|
NCI_THESAURUS |
C2199
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1180503
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | |||
|
C62022
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | |||
|
751452
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | |||
|
m4227
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | Merck Index | ||
|
166
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | |||
|
N0000181819
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | Uncompetitive NMDA Receptor Antagonists [MoA] | ||
|
4470
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | |||
|
DTXSID3022908
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | |||
|
3056
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | |||
|
125-71-3
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | |||
|
SUB07051MIG
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | |||
|
204-752-2
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | |||
|
CHEMBL52440
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | |||
|
N0000182147
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | Sigma-1 Receptor Agonists [MoA] | ||
|
842
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | |||
|
DB00514
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | |||
|
6953
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | |||
|
7355X3ROTS
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | |||
|
Dextromethorphan
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | |||
|
7355X3ROTS
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | |||
|
3289
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
ALTERNATIVE | RxNorm | ||
|
DEXTROMETHORPHAN
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | |||
|
100000092321
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | |||
|
D003915
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | |||
|
5360696
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY | |||
|
236146
Created by
admin on Mon Mar 31 17:45:38 GMT 2025 , Edited by admin on Mon Mar 31 17:45:38 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SUB_CONCEPT->SUBSTANCE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
Metabolizing reaction by CYP2D6: O-demethylation
Pharmacological action: Antitusive agent
MAJOR
Unidentified
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET->WEAK INHIBITOR |
Rat. Prodrug of dextrorphan, which is the actual mediator of most of its dissociative effects through acting as a more potent NMDA receptor antagonist than dextromethorphan itself.
Ki
|
||
|
TARGET -> AGONIST |
Ki
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
TARGET -> INHIBITOR |
Rat
Ki
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
|
||
|
METABOLITE -> PARENT |
SECONDARY METABOLITE CYP3A4 ALSO INVOLED IN PRIMARY
MAJOR
PLASMA
|
||
|
METABOLITE -> PARENT |
MAJOR
PLASMA
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|